This research aims to evaluate the 1-year outcomes of a new transcatheter mitral valve replacement in patients with severe degenerative mitral regurgitation.
Conducted as a randomized trial with an initial cohort of patients diagnosed with severe degenerative mitral regurgitation.
Patients underwent a new transcatheter mitral valve replacement procedure and were followed for one year to assess safety and efficacy.
Outcomes measured included procedural complications, improvement in symptoms, and quality of life post-procedure.
At one year, 80% of patients showed significant improvement in symptoms related to mitral regurgitation (P<0.05).
The procedural complication rate was low at 5%, with no major adverse cardiac events reported.
Patient-reported quality of life scores increased by an average of 40 points on the relevant health questionnaire.